[{"id":"a0eacbf5-c28f-490b-921a-c8bde8e31289","acronym":"JSKN003-102","url":"https://clinicaltrials.gov/study/NCT05744427","created_at":"2023-02-27T15:00:52.581Z","updated_at":"2024-07-02T16:35:00.271Z","phase":"Phase 1/2","brief_title":"To Evaluate the Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05744427 - JSKN003-102","lead_sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anbenitamab repodatecan (JSKN003)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-29"},{"id":"dc92fba4-017b-416f-8921-5caed9a23029","acronym":"","url":"https://clinicaltrials.gov/study/NCT06079983","created_at":"2023-10-12T21:13:53.590Z","updated_at":"2024-07-02T16:35:33.828Z","phase":"Phase 3","brief_title":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","source_id_and_acronym":"NCT06079983","lead_sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • docetaxel • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • vinorelbine tartrate • anbenitamab repodatecan (JSKN003)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2023-10-12"},{"id":"412fc678-d080-4e00-bbf1-0d855cbd6eed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05494918","created_at":"2022-08-10T12:55:23.182Z","updated_at":"2024-07-02T16:36:02.423Z","phase":"Phase 1","brief_title":"First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors","source_id_and_acronym":"NCT05494918","lead_sponsor":"Alphamab (Australia) Co Pty Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anbenitamab repodatecan (JSKN003)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/02/2022","start_date":" 09/02/2022","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2022-10-14"}]